Page last updated: 2024-12-07
4-amino-n-(2,6-dimethylphenyl)phthalimide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-amino-N-(2,6-dimethylphenyl)phthalimide: a potent anticonvulsant against maximal electroshock-induced seizures; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 124031 |
| CHEMBL ID | 283880 |
| SCHEMBL ID | 4151437 |
| MeSH ID | M0252477 |
Synonyms (15)
| Synonym |
|---|
| 158276-70-1 |
| 5-amino-2-(2,6-dimethylphenyl)isoindoline-1,3-dione |
| 4-amino-n-(2,6-dimethylphenyl)phthalimide |
| CHEMBL283880 , |
| add 213063 |
| 5-amino-2-(2,6-dimethylphenyl)isoindole-1,3-dione |
| bdbm50066438 |
| 5-amino-2-(2,6-dimethyl-phenyl)-isoindole-1,3-dione |
| 5-amino-2-(2,6-dimethylphenyl)-1h-isoindole-1,3(2h)-dione |
| add-213063 |
| 1h-isoindole-1,3(2h)-dione, 5-amino-2-(2,6-dimethylphenyl)- |
| URALYBWTMWGVCV-UHFFFAOYSA-N |
| SCHEMBL4151437 |
| DTXSID20166394 |
| 5-amino-2-(2,6-dimethylphenyl)-2,3-dihydro-1h-isoindole-1,3-dione |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " This anti-MES activity is achieved with nontoxic doses, with the optimal effect recorded in rats dosed orally with anti-MES ED50 and protective index (PI) values of 25." | ( Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl)phthalimide and prototype antiepileptic drugs in mice and rats. Bailleux, V; Hamoir, G; Nuyts, JP; Poupaert, JH; Stables, JP; Vallée, L; Vamecq, J, 1995) | 0.54 |
| " Anticonvulsant ED50s (effective doses in at least 50% of animals tested) of compounds in the MES test were determined in rats dosed orally and amounted to 52 (1), 135 (2), 284 (3), 231 (8), 131 (9), 25 (10), 369 (13), 354 (14), and 121 (PHT) micromol/kg, compound 5 presenting with an ED50 value higher than 650 micromol/kg." | ( Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. Lambert, D; Masereel, B; Poupaert, JH; Stables, JP; Vamecq, J, 1998) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Aminopeptidase N | Homo sapiens (human) | IC50 (µMol) | 56.3000 | 0.4000 | 2.1100 | 3.9000 | AID38364 |
| Aminopeptidase N | Sus scrofa (pig) | IC50 (µMol) | 56.3000 | 0.0005 | 3.5354 | 8.9000 | AID38364 |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | IC50 (µMol) | 87.9000 | 0.0001 | 0.4444 | 10.0000 | AID56226 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (23)
Molecular Functions (16)
Ceullar Components (18)
Bioassays (21)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID171628 | Toxicity was determined in rats at a dose of 30 mg/kg after 4 hour. (- denotes no activity in administered animals). | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID211677 | Neurotoxicity determined at 30 minutes after the administration of compound by rotarod test.(++= signify activity at 100 mg/kg) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID168604 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 1 hour by MES test. (++++ denotes activity in 75-100% of administered animals) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID219416 | Cytotoxicity in human embryonic lung flbroblast Wl-38 cells using WST-1 viability assay | 1999 | Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4 | Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs. |
| AID168750 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 15 minutes by MES test. (++++ denotes activity in 75-100% of administered animals) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID56211 | Inhibitory activity against dipeptidyl peptidase IV (DPP- IV) | 1998 | Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3 | Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton. |
| AID168758 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 30 minutes by MES test. (++++ denotes activity in 75-100% of administered animals) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID197748 | Effective dose administered intraperitoneally in the MES model | 2001 | Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2 | Medicinal chemistry of neuronal voltage-gated sodium channel blockers. |
| AID109359 | Anticonvulsant activity determined at 4 hours after the administration of compound using sc Ptz test. (- denotes activity at 300 mg/kg) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID211680 | Neurotoxicity determined at 4 hours after the administration of compound by rotarod test (++= signify activity at 100 mg/kg) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID38364 | Inhibitory activity against aminopeptidase N (APN) in human acute lymphoblastic leukemia MOLT-4 cell line | 1999 | Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4 | Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs. |
| AID56226 | Inhibitory activity against Dipeptidylpeptidase IV (DPP IV) in human acute lymphoblastic leukemia MOLT-4 cell line | 1999 | Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4 | Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs. |
| AID109349 | Anticonvulsant activity determined at 30 minutes after the administration of compound using sc Ptz test. (+++ = activity at 30 mg/kg) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID178278 | Anticonvulsant ED50 activity by MES test in rats dosed orally | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID168754 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 2 hour by MES test. (++++ denotes activity in 75-100% of administered animals) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID168761 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 4 hour by MES test. (++ denotes activity in 25-50% of administered animals). | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID109357 | Anticonvulsant activity determined at 4 hours after the administration of compound using MES test.(++= signify activity at 100 mg/kg) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID38377 | Inhibitory activity against aminopeptidase N assayed by the L-Ala-MCA method. | 1998 | Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3 | Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton. |
| AID217925 | Inhibition of [3H]BTX binding to cardiac voltage-gated sodium channel | 2001 | Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2 | Medicinal chemistry of neuronal voltage-gated sodium channel blockers. |
| AID205272 | Apparent IC50 value by [3H]batrachotoxinin-A-20-alpha-benzoate-binding test performed in rat brain synaptosomes | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| AID109345 | Anticonvulsant activity determined at 30 minutes after the administration of compound using MES test. (+++ = activity at 30 mg/kg) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.40
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.40) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||